Antigen-processing machinery breakdown and tumor growth.
about
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor MilieuUp-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acidAbsence of gamma-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell recognition of select immunodominant epitopesNanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and ImmunotherapyTumor antigen-specific monoclonal antibodies and induction of T-cell immunityImmunogenicity of Human Mesenchymal Stem Cells in HLA-Class I-Restricted T-Cell Responses Against Viral or Tumor-Associated AntigensWhat is the role of alternate splicing in antigen presentation by major histocompatibility complex class I molecules?Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.Identification of E2F1 as an important transcription factor for the regulation of tapasin expression.Different regulation of MHC class I antigen processing components in human tumors.Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas.Mapping and expression pattern analysis of key components of the major histocompatibility complex class I antigen processing and presentation pathway in a representative human renal cell carcinoma cell line.Heat shock protein expression and anti-heat shock protein reactivity in renal cell carcinoma.Genomewide trapping of genes that encode secreted and transmembrane proteins repressed by oncogenic signaling.Trogocytosis of MHC-I/peptide complexes derived from tumors and infected cells enhances dendritic cell cross-priming and promotes adaptive T cell responses.Effect of B7.1 costimulation on T-cell based immunity against TAP-negative cancer can be facilitated by TAP1 expressionA case-control study on association of proteasome subunit beta 8 (PSMB8) and transporter associated with antigen processing 1 (TAP1) polymorphisms and their transcript levels in vitiligo from Gujarat.Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity.ProtEx technology for the generation of novel therapeutic cancer vaccinesTrends in cancer immunotherapyBispecific antibodies engage T cells for antitumor immunotherapy.Post-transcriptional and epigenetic regulation of antigen processing machinery (APM) components and HLA-I in cervical cancers from Uighur womenT cell-tumor interaction directs the development of immunotherapies in head and neck cancer.Diversity in MHC class II antigen presentation.Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo.Early hematopoietic zinc finger protein prevents tumor cell recognition by natural killer cellsImmunity to cancer: attack and escape in T lymphocyte-tumor cell interaction.Therapeutic vaccination with tumor cells that engage CD137.PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cellsPhysiological significance of apoptosis during animal virus infection.Oncoantigens for an immune prevention of cancer.Differential down-modulation of HLA class I and II molecule expression on human tumor cell lines upon in vivo transfer.Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic miceMHC class I-related antigen-processing machinery component defects in feline mammary carcinoma.Vaccination with T cell-defined antigens.Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLsEnhanced expression of interferon-gamma-induced antigen-processing machinery components in a spontaneously occurring cancer.
P2860
Q21131200-4EF058F1-5ED4-4715-9E23-BDD58B3CD652Q24288944-B8C36919-E07B-44E9-A776-83DC60B5E28EQ24674180-4A1D875F-2D54-4578-9D0A-F0500254C028Q26782566-1CAF6016-4FB8-4B8D-8041-33C1F9515A33Q27009908-4563D0BB-8D6E-49E8-BBDC-37225FA13A15Q27489354-2A3288AF-5850-4014-958C-E1CD76445348Q27491004-CBFD68AF-D6B9-44DA-9032-A4172F8ABDA4Q27691330-F964DBD8-B952-4DA0-B5CC-0A8B650BF307Q30318613-129831C8-4C6E-427B-9A40-88BE821F3EBCQ30319116-EFF35C7A-7331-482F-B6EA-AA94D94DFED7Q30425423-F1417591-CFDC-47E0-B44E-91F5035075E5Q30682199-D0ADCACF-E903-45F2-BBB5-6BF434D52E38Q31050911-546F5E87-EF04-4C6B-896E-4526E5D1E9BFQ32028229-44D1CF19-F6BA-4786-8804-671D4AF95DACQ33366578-9E02CBFD-7565-41CF-AB77-CC5A704F9139Q33486534-E5E04218-5A20-4664-91E7-C212D50AAE20Q33897820-1B1D0AE2-3451-4C2F-9BB8-E64584ADBEE3Q34035564-AF5CFD28-6ADE-4BA9-A3C4-E9ADA3AF3C79Q34048819-30CF6F60-1D43-4363-B9C9-FDE889C745E9Q34052702-5CCEB9D7-43A0-4B74-BE9C-36A644D7537AQ34174334-F5EAFD10-D5CF-467C-8272-694F3BFCBD41Q34425118-651D9BBB-4736-4002-ACA7-1D44FF8078B4Q34475726-BDF568A0-2BF3-4EE2-B700-7A97B6BF265AQ34579769-40667423-4866-4E48-8990-4F450390C85CQ34834369-36AE66B7-0891-4B95-AF67-AFFD2A6BBCF3Q34973901-AF8AC323-0629-40F7-B33B-18DADA4AE881Q35005940-BD10727A-C614-4D42-9483-B8C3C65BFB40Q35071688-9754D81D-E76D-4CA6-8F6B-F36FB277F403Q35107110-43FAE4B4-6A42-4497-A1FF-13B53F656BA3Q35136002-9C756695-7950-476B-817B-5835B7BFACD9Q35213606-EF007BA5-2096-4BE4-96B9-891DFF574122Q35232253-70FD2E51-172C-4A3E-88CB-1474D234FD3DQ35402927-59DFB008-D7AB-407A-9010-5079274C2A0DQ35740182-F19C1781-E8E8-4176-8817-19949FE122B6Q35762219-F5CC5BD4-4448-4142-A430-8F5BBF9855FDQ35779384-09332069-7F30-457E-AC80-3B4E3C6C2732Q35799094-A2097CCB-2111-4F3F-AA1C-1500C21794EDQ35939427-5B60B5C3-7B3D-4752-9396-F15F811305AEQ36028423-55295A20-E1D2-41F0-921D-8FB25AACC646Q36143622-45CEE6D5-197D-4B27-866B-F5C09F34CA15
P2860
Antigen-processing machinery breakdown and tumor growth.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Antigen-processing machinery breakdown and tumor growth.
@ast
Antigen-processing machinery breakdown and tumor growth.
@en
Antigen-processing machinery breakdown and tumor growth.
@nl
type
label
Antigen-processing machinery breakdown and tumor growth.
@ast
Antigen-processing machinery breakdown and tumor growth.
@en
Antigen-processing machinery breakdown and tumor growth.
@nl
prefLabel
Antigen-processing machinery breakdown and tumor growth.
@ast
Antigen-processing machinery breakdown and tumor growth.
@en
Antigen-processing machinery breakdown and tumor growth.
@nl
P2093
P1433
P1476
Antigen-processing machinery breakdown and tumor growth.
@en
P2093
P304
P356
10.1016/S0167-5699(00)01692-3
P577
2000-09-01T00:00:00Z